Browse Category:

Categories

[Search within category]

Engineering Human Proteases for Therapeutic Use

A methodology termed “protease evolution via cleavage of an intracellular substrate” (PrECISE) to enable engineering of human protease activity and specificity toward an arbitrary peptide target. 

New Compositions to Treat Heparin Overdose

Heparin is one of the most frequently prescribed medications in the United States. And despite the fact that protamine has displayed adverse side effects and demonstrates low efficacy towards reversing more recently developed low molecular weight heparins (LMWH), protamine remains the only clinically-approved heparin reversal agent. To treat heparin overdose, new heparinoid reversal agents with high potency and low toxicity are needed - particularly for patients receiving LMWH and unfractionated heparin.

Novel Target For Contraceptives And Painkillers

The steroid progesterone (P4) is a major component of follicular fluid and is released by ovaries and cumulus cells surrounding the oocyte.  P4 is known to cause rapid and robust elevation of sperm cytoplasmic calcium levels through binding to a non-genomic receptor.  This rise in intracellular calcium leads to changes in sperm motility and primes the cell for acrosomal exocytosis, which is required for fertilization.     UC Berkeley researchers have identified an enzyme as a P4 non-genomic receptor.  The enzyme was found to possess progesterone-stimulated endocannabinoid hydrolase activity, and regulate human sperm activation.  The technology includes methods of modulating the level and/or activity of the enzyme in a cell in an individual. 

Novel TLR-4 Ligands as Immune Activators

Toll-like receptors (TLRs) are a set of conserved cellular proteins that play an important role in the recognition of microbial pathogens and in initiating the first line of host innate immune response. Although early work suggested that modulating the response could have clinical utility, few agents have been able to clear regulatory hurdles to development. A comprehensive screen for small molecules that activated NF-kB identified substituted 4-aminoquinazolines with potential clinical utility to modulate innate immune responses.

Novel compounds for the treatment of fungal infections

Treatment of fungal infections remains a medical challenge and better and more efficacious treatments are needed. Antifungal agents provide relief from fungal infections that can potentially infect almost any part of the human body, but, systemic fungal infections can be life threatening. A commonly prescribed antifungal drug for systemic fungal infections is fluconazole. Fluconazole tends to be well tolerated; however there have been reports of various undesirable side effects as well as the emergence of fluconazole resistant fungal strains.

Improvements of cognitive function in age-related disorders and Alzheimer's disease

Cognitive deficits associated with aging and other age-related disorders involve deficits in processing sensory information, attention, consolidation of memory, recall of information, and executive functions such as planning, problem solving and self-monitoring among others. There is a large unmet medical need to identify therapies and novel therapeutic regimes for the treatment of cognitive dysfunction, e.g., cognitive deficits related to aging, age-related disorders and Alzheimer's disease. Previously published research suggests a correlation between neurological disorders and trimethylation of histone H3K9 in the brain. Therefore, an inhibitor of histone methyl transferase SUV39h1 and its effects on the progression of age-related disorders was investigated.

Metal Binders for Drug Discovery

The use of compound or fragment libraries are being increasingly used in drug discovery as rational drug design has become more sophisticated and high throughput techniques have made screening these types of libraries faster and less labor intensive.

Methods Of Treating Cancer Using Novel Hsp90/Cdc37 Inhibitors Derived From Cucurbitacin Family

This invention identifies a novel group of cuburbitacin derivatives that inhibit the interaction between Hsp90 and Cdc37, and may be applied to cancer treatment.

Plasma Biomarkers for Monitoring Cancer Chemotherapy Efficacy

Highly sensitive protein biomarkers that can be used to monitor the extent of apoptosis in order to optimize chemotherapy regimen in cancer patients

Novel Agonists of Toll-like Receptors (TLRs) for Cancer Immunotherapy and Vaccination

Toll-like receptors are part of the innate immune system, which is a widely-deployed and evolutionarily conserved means of defending against pathogens. And, although cancer cells are notoriously adept at evading the immune system, UC researchers have identified novel TLR agonists that use innate immunity to target tumor cells and provide immunotherapeutic options. The approach is validated by the potent anti-tumor activity of such compounds as imiquimod and resiquimod but these drugs are limited by inherent short half-lives and there is a distinct need for compounds with increased efficacy at these proven targets.

Novel Agonists of Toll-like Receptors (TLRs) for Infectious Disease and Vaccination

Toll-like receptors (TLRs) are a set of conserved cellular proteins that play an important role in the recognition of microbial pathogens and in initiating the first line of host innate immune response. Although early work suggested that modulating the response could have clinical utility, few agents have been able to clear regulatory hurdles to development and TLR-7 agonists have been challenged by side-effects of cardiotoxicity and myelosuppression.

A Non-Natural Linker for the Synthesis of Pure, Constrained Tricyclic Peptides

UCLA researchers have developed a novel non-natural linker as the scaffold for the synthesis of pure, single-regioisomer-product of tricyclic peptides, which greatly enhances the efficiency of peptide modification and their pharmaceutical value.

Novel Neuropathy Treatment Using Soluble Epoxide Inhibitors

Researchers at the University of California, Davis have developed a new method and composition of blocking pain using a novel class of analgesic agents and a synergistic combination involving soluble epoxide inhibitors.

Small Molecule Inhibitors Targeting Digestive System Enzymes to Control Obesity and Type II Diabetes

Researchers in the Department of Chemistry and Biochemistry have identified a compound that can block the enzyme that converts “hunger hormone” precursors to active hormones.

Preparation and Activity of Novel Photosensitizer Acting as a Broad Spectrum Antiviral Agent against Enveloped Viruses

Professor Michael Jung’s group at UCLA has developed a novel class of compounds with broad spectrum antiviral activity toward enveloped viruses.

Enhancing Efficacy of Immunotherapy and Chemo-Therapy Treatments

Researchers at the University of California, Davis campus have discovered the use of certain compounds as immunomodulators for enhancing the efficacy of immunotherapy and chemoradiotherapy.

Novel Short Netrin-1 Derived Peptides for the Treatment of Myocardial Infarction

UCLA researchers in the Department of Anesthesiology have identified three novel short netrin-1 derived peptides for the treatment of myocardial infarction with improved scalability and fewer adverse side effects.

SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS

Therapeutic inhibitors of Urea Transporter A (UT-A) as highly effective diuretics with reduced risk of cardiac and neurological side effects for treatment of cardiovascular and renal disorders

Activating HIV Latency Using Drug Encapsulated Nanoparticles

UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics have devised a novel method to target the HIV virus in patients using nanoparticles loaded with therapeutic agents.

CYP3A4 Epoxygenase Inhibitors for ER+ Breast Cancer Treatment

Small molecule CYP34A inhibitor oncology therapeutics are being developed in collaboration between scientists at UC Irvine and U of Minnesota. These molecules have been shown effective against ER+ xenograft models of breast cancer. Due to their mechanism of action, these molecules may enhance treatment with tamoxifen and paclitaxel to decrease risk of recurrence.

Method For Delivery Of Drugs Across The Intact Tympanic Membrane

The current treatment for ear infections such as systemic antibiotics can have serious side effects, especially if used prophylactically to prevent recurrent middle ear infections. Also, the amount of drug that actually reaches the middle ear is not high, and often ineffective. In children, especially, systemic antibiotics lead to drug resistance. Other treatment options include tympanostomy tubes (surgery) which requires general anesthesia, with risks. Therefore local delivery of drugs to the middle ear would address many of these issues. 

Small Molecules as chemotherapeutics agents for cancer treatment by restoring p53 function.

The tumor suppressor p53 normally functions to prohibit unregulated growth of cells. p53 is the most frequently mutated gene in human cancers. The most frequent p53 mutation is a missense mutation known as R175H. We have discovered 11 small molecules that interact with and stabilize R175H protein. The stabilization of R175H by these small molecules restores p53 function and can be a potential drug candidate. Currently, there are no known drug targets that specifically work on p53 mutants and our compounds will be the first to have specific targeting capacity.

Imprinted Polymer Nanoparticles

Synthetic polymer nanoparticles (NPs) capable of recognizing specific biomacromolecules and neutralizing their activities can be used as substitutes for natural antibodies.

Novel Chitosan Derivative as a Systemic Drug Delivery Agent and an Antibiotic Treatment

Researchers at the University of California, Irvine have developed a novel chitosan derivative that may be used simultaneously as a systemic drug delivery agent and a systemic antibiotic treatment.

Small Molecule Suppressors of Cardiac Fibrillation

UCLA researchers have developed a novel small molecule as a potential therapeutic treatment for cardiac fibrillation.

  • Go to Page:

University of California
Innovation Alliances and Services

1111 Franklin Street, 5th Floor,Oakland,CA 94607-5200 |
http://www.ucop.edu/ott/
Tel: 510.587.6000 | Fax: 510.587.6090 | UC.technologies@ucop.edu